SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
We are pleased to enclose herewith our Press Release titled, 'DUSA Pharmaceuticals, Inc. Awarded Preliminary Injunctive Relief Prohibiting Biofrontera from Using Its Trade Secrets', which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you, Sun Pharmaceutical Industries Ltd - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shanghvi Finance Pvt Ltd SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Raksha Valia SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Receipt Of US FDA Approval Of ELEPSIATM XR 1000Mg And ELEPSIATM XR 1500Mg
We are pleased to inform you that the U.S. Food and Drug Administration (USFDA) has granted approval for the New Drug Application (NDA), to a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd. (SPIL), for ElepsiaTM XR 1000 mg (levetiracetam 1000 mg) and ElepsiaTM XR 1500 mg (levetiracetam 1500 mg). This product was filed from SPIL's Halol (Gujarat, India) facility. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shanghvi Finance Pvt Ltd Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Raksha Sudhir Valia - PAC
Sun Pharma: Limited clarity on whistleblower letter, as share price falls
India's largest pharma company, Sun Pharma (which is in 15+ stock screeners) hit a new year low in the past week, falling by over 16% in share price. It is in strongly bearish, oversold territory, as indicated by the RSI and MFI. It is also among the companies where promoters have increased their pledged stocks, signalling some financial distress. What is still out there in terms of pending disclosures for Sun Pharma? There is the rumored 150 page long (!) whistleblower letter to SEBI, based on which the agency is reportedly opening an investigation. Rumors abound in Dalal Street that excerpts of the whistleblower letter were circulating in whatsapp groups of foreign fund managers at least a month before the news. Sun Pharma's share price has been falling steadily over the past three months, and open interest(outstanding positions) in Sun Pharma futures jumped 30 per cent in November compared from October There is also the issue of missing explanations from the management on unsecured loans, and its relationship with Aditya Medisales, who also holds shares in the company. Unless these get more clarity in the public space there is little anyone can say about how low the price of Sun Pharma stock can go. Broker's call: Sun Pharma (Reduce)
EquirusSun Pharma (Reduce)CMP: 411.3Target: 479Sun Pharmaceutical Industries is a pharmaceuticals company. The company's business segments include Meet Sudhir Valia, Sun Pharma's director, one of India's prolific investors
His real estate transactions in the last couple of years further bought him into the spotlight Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shanghvi Finance Pvt Ltd